Page last updated: 2024-08-23

pirfenidone and transforming growth factor beta

pirfenidone has been researched along with transforming growth factor beta in 64 studies

Research

Studies (64)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (6.25)	18.2507
2000's	19 (29.69)	29.6817
2010's	33 (51.56)	24.3611
2020's	8 (12.50)	2.80

Authors

Authors	Studies
Fukagawa, M; Hata, S; Iwasaki, Y; Kuroda, T; Kurokawa, K; Margolin, SB; Nemoto, M; Shimizu, F; Shimizu, T; Shirai, K; Yamauchi, S	1
Fukagawa, M; Hata, S; Kuroda, T; Kurokawa, K; Margolin, SB; Shimizu, T	1
Ambler, JS; Shiels, IA; Taylor, SM; Zhang, S	1
Giri, SN; Gurujeyalakshmi, G; Iyer, SN	1
Giri, SN; Hyde, DM; Iyer, SN	1
Enjoji, M; Iwamoto, H; Kato, M; Nakamuta, M; Nakashima, Y; Nawata, H; Sugimoto, R; Tada, S	1
Boichot, E; Corbel, M; Germain, N; Lagente, V; Lanchou, J; Malledant, Y	1
Horikawa, T; Nakazato, H; Oku, H; Suzuki, R; Tsuruta, Y	1
Andoh, TF; Bennett, WM; Shihab, FS; Yi, H	1
Bendia, E; Benedetti, A; Casini, A; Ceni, E; Di Sario, A; Marzioni, M; Ridolfi, F; Saccomanno, S; Sterpetti, P; Svegliati Baroni, G; Taffetani, S; Trozzi, L	1
Brien, JF; Card, JW; Margolin, SB; Massey, TE; Racz, WJ	1
McGowan, TA; Sharma, K; Zhu, Y	1
Bicknell, GR; Brook, NR; Nicholson, ML; Waller, JR	1
Cheng, Y; Drew, P; Gaugler, AC; Liu, H; Visner, GA	1
Latham, CW; Margolin, SB; Visner, GA; Zander, DS; Zhou, H	1
Gelfand, EW; Hirano, A; Ito, W; Kanehiro, A; Kataoka, M; Nakashima, H; Okada, C; Ono, K; Tanimoto, M; Tanimoto, Y; Yoshida, A	1
Hoey, AJ; Irwin, NG; Van Erp, C	1
Antoniu, SA	1
Bratt, JM; Decile, KC; Giri, SN; Grewal, H; Mansoor, JK; Margolin, SB; Pinkerton, KE; Schelegle, ES; Walby, WF	1
Burghardt, I; Frank, B; Opitz, CA; Tritschler, F; Weller, M; Wick, W	1
Aquilina, K; Hobbs, C; Thoresen, M; Tucker, A; Whitelaw, A	1
Armendáriz-Borunda, J; Castrejón-Gómez, E; López-Reyes, A; Ruiz-Corro, L; Salazar-Montes, A	1
Alvarez-Rodríguez, A; Arellano-Olivera, I; Armendáriz-Borunda, J; Bautista, CA; Bueno-Topete, M; García-Rocha, S; Godoy, J; González-García, I; Islas-Carbajal, MC; Lucano, S; Medina-Preciado, D; Muñoz-Valle, JF; Oregón-Romero, E; Rincón, AR; Salazar, A; Troyo-SanRoman, R; Vázquez-Del Mercado, M	1
Chikanishi, T; Fujimori, A; Itoh, H; Iwatsuki, Y; Nakajima, H; Okada, M; Takakuta, K; Tanokura, A; Yamamoto, M	1
Declèves, AE; Sharma, K	1
Beaulieu, MC; Levin, A	1
Hu, GX; Li, JW; Lu, ZQ; Shen, XW; Sun, W; Tong, SH; Xiao, M; Yu, XC	1
Kossen, K; Pan, L; Ruhrmund, DW; Schaefer, CJ; Seiwert, SD	1
Choi, JS; Jung, KI; Kim, HK; Shin, SY	1
Adamali, HI; Maher, TM	1
Chuang, PY; He, JC; Menon, MC	1
Endo, K; Iwai, N; Ji, X; Kito, N; Li, J; Ma, X; Naito, Y; Weng, H; Yanagawa, N; Yu, Y	1
Tampe, D; Zeisberg, M	1
Conte, E; Fagone, E; Fruciano, M; Gili, E; Iemmolo, M; Vancheri, C	1
Leask, A	1
Choi, SH; Jang, J; Lee, HJ; Lee, YJ; Nam, JK	1
Bojja, J; Labala, S; Mandapalli, PK; Venuganti, VV	1
Bollmann, G; Cosín-Roger, J; Fagagnini, S; Hausmann, M; Hünerwadel, A; Lang, S; Lutz, C; Mamie, C; Meier, R; Rogler, G; Tchouboukov, A; Weber, A; Weber, FE	1
Antonia, SJ; Boateng, K; Mediavilla-Varela, M; Noyes, D	1
Bacon, KB; Boehme, SA; DiTirro, DN; Franz-Bacon, K; Ly, TW	1
Chen, G; Deng, Y; Gu, G; Guo, K; Hu, Q; Li, G; Li, J; Li, R; Li, Y; Ren, J; Wang, G; Wu, L	1
Calik, E; Guvenal, T; Hasdemir, PS; Koltan, SO; Koyuncu, FM; Ozbilgin, K; Ozkut, M; Uner, MA	1
Le, A; Takai, K; Weaver, VM; Werb, Z	1
Didiasova, M; Kwapiszewska, G; Lauth, M; Markart, P; Schaefer, L; Seeger, W; Singh, R; Wilhelm, J; Wujak, L; Wygrecka, M; Zakrzewicz, D	1
Guthoff, RF; Hovakimyan, M; Kowtharapu, BS; Schmitz, KP; Stachs, O; Stahnke, T; Wree, A; Wurm, J	1
Alexander, KA; Antin, JH; Blazar, BR; Cutler, CS; Du, J; Flynn, R; Hill, GR; Koreth, J; Lineburg, KE; Loschi, M; Luznik, L; MacDonald, KP; Maillard, I; Meng, J; Miklos, D; Panoskaltsis-Mortari, A; Paz, K; Ritz, J; Robinson, TM; Roy, S; Schacker, TW; Serody, JS; Vulic, A	1
Boor, P; Floege, J; Goldschmeding, R; Klinkhammer, BM	1
Kang, L; Liu, Y; Lu, F; Wang, Y; Wang, Z	1
Epstein Shochet, G; Shitrit, D; Wollin, L	1
Lederer, DJ; Martinez, FJ	1
Burridge, K; Doerschuk, CM; Monaghan-Benson, E; Wittchen, ES	1
Isaka, Y	1
Pata, YS; Türkmen, E	1
Berkowski, WM; Gibson, DJ; Plummer, CE; Proietto, LR; Schultz, GS; Seo, S; Whitley, RD	1
Oupicky, D; Sun, M; Ullah, A; Wang, K; Wu, P	1
Abdel-Aziz, AH; Abdelghany, TM; Ashour, AA; Salah, MM; Salama, SA	1
Bao, Y; Chen, Y; Gao, C; Huang, L; Huang, X; Song, Y; Wu, L; Zhu, S	1
AlQudah, M; Czubryt, MP; Hale, TM	1
Hamidi, SH; Kadamboor Veethil, S	1
Allard, B; Batteux, F; Blanco, P; Chizzolini, C; Constans, J; Contin-Bordes, C; Duffau, P; Forcade, E; Groppi, A; Henrot, P; Izotte, J; Jeljeli, M; Jolivel, V; Laurent, P; Lazaro, E; Leleu, D; Levionnois, E; Manicki, P; Pradeu, T; Richez, C; Schaeverbeke, T; Seneschal, J; Truchetet, ME	1
Chai, D; Guo, Z; Han, L; Huang, N; Li, H; Li, J; Li, L; Lv, Y; Wang, G; Xu, D; Zheng, J; Zheng, W; Zhou, X	1
Ashish, S; Chanda, D; Chiles, J; Kumar, PL; McDonald, MN; Mobley, JA; Neptune, ER; Thannickal, VJ; Wilson, AC	1
Ahir, M; Bonnen, MD; Ebrahimpour, A; Eissa, NT; Ghebre, YT; Jegga, AG; Montesi, SB; Raghu, G; Wang, M	1
Cheng, Z; Hu, Z; Li, D; Long, J; Long, S; Luo, D; Wang, Y; Zeng, X; Zeng, Z; Zhang, S; Zhou, J	1

Reviews

13 review(s) available for pirfenidone and transforming growth factor beta

Article	Year
Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy. Current diabetes reports, 2004, Volume: 4, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diabetic Nephropathies; Disease Models, Animal; Humans; Kidney Failure, Chronic; Pyridones; Transforming Growth Factor beta	2004
Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:7 Topics: Administration, Oral; Amiodarone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Cell Line; Clinical Trials, Phase II as Topic; Connective Tissue Growth Factor; Cricetinae; Cyclophosphamide; Drug Evaluation, Preclinical; Drugs, Investigational; Fibroblasts; Hermanski-Pudlak Syndrome; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Lung Transplantation; Mice; Orphan Drug Production; Photosensitivity Disorders; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Transforming Growth Factor beta; Treatment Outcome; Tumor Necrosis Factor-alpha	2006
New pharmacological treatments for improving renal outcomes in diabetes. Nature reviews. Nephrology, 2010, Volume: 6, Issue:6 Topics: Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Biomarkers; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Fumarates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Protein Kinase C; Pyridones; Renin; Transforming Growth Factor beta	2010
Antifibrotic activities of pirfenidone in animal models. European respiratory review : an official journal of the European Respiratory Society, 2011, Volume: 20, Issue:120 Topics: Administration, Oral; Animals; Cardiomyopathies; Disease Models, Animal; Extracellular Matrix Proteins; Humans; Kidney Diseases; Liver Cirrhosis; Pulmonary Fibrosis; Pyridones; Signal Transduction; Transforming Growth Factor beta	2011
Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug design, development and therapy, 2012, Volume: 6 Topics: Acetylcysteine; Amino Acid Oxidoreductases; Animals; Antiviral Agents; Gastroesophageal Reflux; Humans; Idiopathic Pulmonary Fibrosis; Interleukin-13; Lung Transplantation; MicroRNAs; Protein Kinase Inhibitors; Pyridones; Transforming Growth Factor beta	2012
Molecular targets for treatment of kidney fibrosis. Journal of molecular medicine (Berlin, Germany), 2013, Volume: 91, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; beta Catenin; Carrier Proteins; Connective Tissue Growth Factor; Fibrosis; Gene Expression Regulation; Humans; Kidney; Molecular Targeted Therapy; NF-kappa B; ortho-Aminobenzoates; Protective Agents; Protein Serine-Threonine Kinases; Pyridones; Signal Transduction; Transforming Growth Factor beta	2013
Potential approaches to reverse or repair renal fibrosis. Nature reviews. Nephrology, 2014, Volume: 10, Issue:4 Topics: Anti-Inflammatory Agents; Bone Morphogenetic Protein 7; Connective Tissue Growth Factor; Disease Progression; Endothelin-1; Epigenesis, Genetic; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Kidney; Kidney Diseases; Kidney Failure, Chronic; Microcirculation; Phosphodiesterase Inhibitors; Pyridones; Transforming Growth Factor beta	2014
Getting to the heart of the matter: new insights into cardiac fibrosis. Circulation research, 2015, Mar-27, Volume: 116, Issue:7 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Arrhythmias, Cardiac; Atrophy; Cicatrix; Connective Tissue Growth Factor; Endothelin Receptor Antagonists; Endothelin-1; Fibrosis; Humans; Hypoxia; Models, Cardiovascular; Molecular Targeted Therapy; Myocardium; Myofibroblasts; Platelet-Derived Growth Factor; Pyridones; Rats; Signal Transduction; Transforming Growth Factor beta	2015
Treatment of Renal Fibrosis-Turning Challenges into Opportunities. Advances in chronic kidney disease, 2017, Volume: 24, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Biomarkers; Connective Tissue Growth Factor; Elasticity Imaging Techniques; Endpoint Determination; Extracellular Matrix; Fibrosis; Galectin 3; Humans; Kidney; Magnetic Resonance Imaging; Polysaccharides; Pyridones; Renal Insufficiency, Chronic; Transforming Growth Factor beta	2017
Idiopathic Pulmonary Fibrosis. The New England journal of medicine, 2018, May-10, Volume: 378, Issue:19 Topics: Diagnosis, Differential; Dyspnea; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Oxygen Inhalation Therapy; Prognosis; Pyridones; Risk Factors; Tomography, X-Ray Computed; Transforming Growth Factor beta	2018
Targeting TGF-β Signaling in Kidney Fibrosis. International journal of molecular sciences, 2018, Aug-27, Volume: 19, Issue:9 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Fibrosis; Humans; Kidney; Kidney Diseases; Molecular Targeted Therapy; Pyridones; Signal Transduction; Transforming Growth Factor beta	2018
Targeting the renin-angiotensin-aldosterone system in fibrosis. Matrix biology : journal of the International Society for Matrix Biology, 2020, Volume: 91-92 Topics: Amides; Angiotensins; Animals; Benzimidazoles; Biphenyl Compounds; Extracellular Matrix; Extracellular Matrix Proteins; Fibroblasts; Fibrosis; Fumarates; Gene Expression Regulation; Humans; Kidney; Liver; Molecular Targeted Therapy; Myocardium; Pyridones; Renin-Angiotensin System; Signal Transduction; Skin; Tetrazoles; Transforming Growth Factor beta	2020
Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective. Pharmacological reports : PR, 2021, Volume: 73, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; COVID-19; COVID-19 Drug Treatment; Humans; Inflammation; Lung Injury; Pyridones; SARS-CoV-2; Signal Transduction; Transforming Growth Factor beta	2021

Other Studies

51 other study(ies) available for pirfenidone and transforming growth factor beta

Article	Year
Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney international. Supplement, 1997, Volume: 63 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Northern; Body Weight; Collagen; Creatinine; Fibrosis; Hydroxyproline; Kidney; Male; Nephrectomy; Pyridones; Rats; Rats, Wistar; RNA, Messenger; Transforming Growth Factor beta	1997
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney international, 1998, Volume: 54, Issue:1 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Collagen; Disease Models, Animal; Fibrosis; Gelatinases; Hydroxyproline; Inulin; Kidney Cortex; Kidney Function Tests; Ligation; Male; Matrix Metalloproteinase 2; Metalloendopeptidases; Pyridones; Rats; Rats, Sprague-Dawley; RNA, Messenger; RNA, Ribosomal, 18S; RNA, Ribosomal, 28S; Transforming Growth Factor beta; Ureter; Ureteral Obstruction	1998
Pirfenidone reduces fibronectin synthesis by cultured human retinal pigment epithelial cells. Australian and New Zealand journal of ophthalmology, 1998, Volume: 26 Suppl 1 Topics: Antineoplastic Agents; Cells, Cultured; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Fibronectins; Humans; Pigment Epithelium of Eye; Pyridones; Transforming Growth Factor beta	1998
Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. The Journal of pharmacology and experimental therapeutics, 1999, Volume: 291, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Bronchoalveolar Lavage Fluid; Cricetinae; Down-Regulation; Lung; Macrophages; Male; Mesocricetus; Pulmonary Fibrosis; Pyridones; Transcription, Genetic; Transforming Growth Factor beta	1999
Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation, 2000, Volume: 24, Issue:5 Topics: Administration, Oral; Animal Feed; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Bronchoalveolar Lavage Fluid; Capillary Permeability; Cricetinae; Inflammation; Macrophages, Alveolar; Male; Mesocricetus; Neutrophil Infiltration; Pulmonary Fibrosis; Pyridones; Transforming Growth Factor beta	2000
Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clinical and experimental pharmacology & physiology, 2001, Volume: 28, Issue:7 Topics: Animals; Blotting, Northern; Body Weight; Collagen; Dimethylnitrosamine; Hydroxyproline; Liver Cirrhosis; Male; Pyridones; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta	2001
Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice. European journal of pharmacology, 2001, Aug-24, Volume: 426, Issue:1-2 Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bronchoalveolar Lavage Fluid; Cell Count; Inflammation Mediators; Lipopolysaccharides; Lung; Lung Diseases; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, Inbred BALB C; Phenylalanine; Pyridones; Thiophenes; Tissue Inhibitor of Metalloproteinases; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha	2001
Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. European journal of pharmacology, 2002, Jun-20, Volume: 446, Issue:1-3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Galactosamine; Interferon-gamma; Interleukin-10; Interleukin-12; Lipopolysaccharides; Liver; Liver Failure; Mice; Mice, Inbred C57BL; Necrosis; Pyridones; Shock, Septic; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha	2002
Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2002, Volume: 2, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biglycan; Calcinosis; Creatinine; Cyclosporine; Extracellular Matrix Proteins; Humans; Immunohistochemistry; Immunosuppressive Agents; Kidney; Kidney Diseases; Kidney Tubules; Male; Proteoglycans; Pyridones; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transcription, Genetic; Transforming Growth Factor beta; Transforming Growth Factor beta1	2002
Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. Journal of hepatology, 2002, Volume: 37, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cells, Cultured; Collagen Type I; Culture Media; Gene Expression; Hepatocytes; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Platelet-Derived Growth Factor; Protein Kinase C; Pyridones; Rats; Rats, Sprague-Dawley; Receptor, Platelet-Derived Growth Factor beta; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger; Sodium-Hydrogen Exchangers; Transforming Growth Factor beta; Transforming Growth Factor beta1	2002
Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicological sciences : an official journal of the Society of Toxicology, 2003, Volume: 75, Issue:1 Topics: Acute Disease; Amiodarone; Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Cricetinae; Disease Models, Animal; Hydroxyproline; Male; Membrane Potentials; Mitochondria; Oxygen Consumption; Pulmonary Fibrosis; Pyridones; RNA, Messenger; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1	2003
The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity. The Journal of surgical research, 2005, May-15, Volume: 125, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Collagen Type III; Collagenases; Fibrosis; Gene Expression Regulation, Enzymologic; Immunosuppressive Agents; Kidney Diseases; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyridones; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tacrolimus; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta	2005
Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2005, Volume: 5, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginase; Arginine; Cells, Cultured; Collagen; Down-Regulation; Gene Expression Regulation; Graft Rejection; Lung Transplantation; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pulmonary Fibrosis; Pyridones; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Signal Transduction; Transforming Growth Factor beta; Transforming Growth Factor beta1; Transplantation, Homologous; Tumor Necrosis Factor-alpha	2005
Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2005, Volume: 24, Issue:10 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclosporine; Disease Models, Animal; Female; Graft Rejection; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyridones; Sirolimus; Trachea; Transforming Growth Factor beta	2005
Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. American journal of respiratory cell and molecular biology, 2006, Volume: 35, Issue:3 Topics: Allergens; Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cell Proliferation; Cytokines; Eosinophils; Goblet Cells; Hyperplasia; Immunoglobulin E; Interleukin-13; Interleukin-4; Interleukin-5; Leukocytes, Mononuclear; Lymphocytes; Mice; Mice, Inbred BALB C; Ovalbumin; Platelet-Derived Growth Factor; Pyridones; Transforming Growth Factor beta; Transforming Growth Factor beta1	2006
Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle & nerve, 2006, Volume: 34, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiomyopathies; Disease Models, Animal; Fibrosis; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscular Dystrophy, Animal; Muscular Dystrophy, Duchenne; Myocardium; Pyridones; RNA, Messenger; Transforming Growth Factor beta; Ventricular Dysfunction, Left	2006
Influence of pirfenidone on airway hyperresponsiveness and inflammation in a Brown-Norway rat model of asthma. Pulmonary pharmacology & therapeutics, 2007, Volume: 20, Issue:6 Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchi; Bronchial Hyperreactivity; Bronchial Provocation Tests; Collagen; Disease Models, Animal; Inflammation; Lung; Male; Mucins; Muscle, Smooth; Ovalbumin; Pyridones; Random Allocation; Rats; Rats, Inbred BN; Respiratory Mucosa; Transforming Growth Factor beta	2007
Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochemical and biophysical research communications, 2007, Mar-09, Volume: 354, Issue:2 Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mink; Pyridones; Transforming Growth Factor beta	2007
Do drugs that block transforming growth factor beta reduce posthaemorrhagic ventricular dilatation in a neonatal rat model? Acta paediatrica (Oslo, Norway : 1992), 2008, Volume: 97, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cerebral Ventricles; Dilatation, Pathologic; Disease Models, Animal; Losartan; Pyridones; Random Allocation; Rats; Rats, Wistar; Transforming Growth Factor beta	2008
Potent antioxidant role of pirfenidone in experimental cirrhosis. European journal of pharmacology, 2008, Oct-24, Volume: 595, Issue:1-3 Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Bilirubin; Carbon Tetrachloride; Catalase; Collagen Type I; Common Bile Duct; Hepatocyte Growth Factor; Ligation; Liver; Liver Cirrhosis, Experimental; Malondialdehyde; NF-kappa B; Nitric Oxide Synthase Type II; Nitrites; Onium Compounds; Oxidative Stress; Proto-Oncogene Proteins c-met; Pyridones; Rats; Rats, Wistar; Superoxide Dismutase; Transforming Growth Factor beta	2008
Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2008, Volume: 56, Issue:7 Topics: Adult; Aged; Angiotensinogen; Anti-Inflammatory Agents, Non-Steroidal; Base Sequence; DNA Primers; Female; Hepatitis C; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Male; Mexico; Middle Aged; Plasminogen Activator Inhibitor 1; Polymorphism, Genetic; Pyridones; Transforming Growth Factor beta	2008
Renoprotective properties of pirfenidone in subtotally nephrectomized rats. European journal of pharmacology, 2010, Mar-10, Volume: 629, Issue:1-3 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Differentiation; Cell Line; Chronic Disease; Disease Progression; Enalapril; Epithelial Cells; Fibrosis; Kidney; Kidney Failure, Chronic; Male; Mesoderm; Nephrectomy; Proteinuria; Pyridones; Rats; Rats, Wistar; Transforming Growth Factor beta	2010
Trials and tribulations of new agents, novel biomarkers, and retarding renal progression. Journal of the American Society of Nephrology : JASN, 2011, Volume: 22, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Biopsy; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Humans; Kidney; Pyridones; Transforming Growth Factor beta	2011
[The study of effects of pirfenidone on the pulmonary fibrosis induced by paraquat in mice]. Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases, 2011, Volume: 29, Issue:2 Topics: Animals; Disease Models, Animal; Lung; Male; Mice; Mice, Inbred ICR; Paraquat; Pulmonary Fibrosis; Pyridones; Transforming Growth Factor beta	2011
Effects of an anti-transforming growth factor-β agent (pirfenidone) on strabismus surgery in rabbits. Current eye research, 2012, Volume: 37, Issue:9 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Follow-Up Studies; Inflammation; Oculomotor Muscles; Postoperative Complications; Pyridones; Rabbits; Strabismus; Transforming Growth Factor beta; Wound Healing	2012
Renoprotective mechanisms of pirfenidone in hypertension-induced renal injury: through anti-fibrotic and anti-oxidative stress pathways. Biomedical research (Tokyo, Japan), 2013, Volume: 34, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Catalase; Fibrosis; Gene Expression Regulation; Hypertension, Renal; Kidney; Male; Matrix Metalloproteinase 9; Oxidative Stress; Proteinuria; Pyridones; Rats; Rats, Inbred Dahl; Signal Transduction; Smad2 Protein; Smad3 Protein; Sodium Chloride, Dietary; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha	2013
Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2014, Jul-16, Volume: 58 Topics: Actins; Anti-Inflammatory Agents, Non-Steroidal; Cell Differentiation; Cell Proliferation; Cell Survival; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Fibroblasts; Humans; Lung; Myofibroblasts; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Pyridones; Smad3 Protein; Transforming Growth Factor beta	2014
Pirfenidone enhances the efficacy of combined radiation and sunitinib therapy. Biochemical and biophysical research communications, 2015, Jun-26, Volume: 462, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Line, Tumor; Collagen; Combined Modality Therapy; Indoles; Mice; Microvessels; Pyridones; Pyrroles; Radiation Tolerance; Sunitinib; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A	2015
Effect of pirfenidone delivered using layer-by-layer thin film on excisional wound healing. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2016, Feb-15, Volume: 83 Topics: Alginates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chitosan; Collagen; Drug Delivery Systems; Drug Liberation; Female; Glucuronic Acid; Hexuronic Acids; Hydrogels; Mice, Inbred C57BL; Polyethylene Glycols; Povidone-Iodine; Pyridones; Skin; Transforming Growth Factor beta; Wound Healing	2016
Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis. Inflammatory bowel diseases, 2016, Volume: 22, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cell Proliferation; Collagen; Disease Models, Animal; Female; Fibrosis; Immunoenzyme Techniques; Intestinal Diseases; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyridones; Transforming Growth Factor beta	2016
The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC cancer, 2016, Mar-02, Volume: 16 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Coculture Techniques; Disease Models, Animal; Drug Synergism; Fibroblasts; Humans; Neoplasms; Pyridones; Transforming Growth Factor beta; Xenograft Model Antitumor Assays	2016
MAP3K19 Is a Novel Regulator of TGF-β Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis. PloS one, 2016, Volume: 11, Issue:5 Topics: A549 Cells; Animals; Bleomycin; Bronchoalveolar Lavage; Cell Line, Tumor; Disease Models, Animal; Epithelial Cells; Female; HeLa Cells; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Injury; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Pyridones; Signal Transduction; Transforming Growth Factor beta; Up-Regulation	2016
Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-β signaling in a murine colitis model. Biochemical pharmacology, 2016, Oct-01, Volume: 117 Topics: Administration, Oral; Administration, Rectal; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cell Proliferation; Cell Survival; Colitis; Collagen; Colon; Disease Models, Animal; Female; Fibrosis; Gastrointestinal Agents; Humans; Intestinal Mucosa; Mice, Inbred C57BL; Pyridones; Random Allocation; Signal Transduction; Specific Pathogen-Free Organisms; Transforming Growth Factor beta	2016
Effect of Pirfenidone on Vascular Proliferation, Inflammation and Fibrosis in an Abdominal Adhesion Rat Model. Journal of investigative surgery : the official journal of the Academy of Surgical Research, 2017, Volume: 30, Issue:1 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Female; Inflammation; Injections, Intraperitoneal; Interleukin-17; Neovascularization, Pathologic; Peritoneum; Postoperative Complications; Pyridones; Rats; Rats, Wistar; Tissue Adhesions; Transforming Growth Factor beta; Treatment Outcome; Uterus	2017
Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget, 2016, Dec-13, Volume: 7, Issue:50 Topics: Animals; Antineoplastic Agents; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Proliferation; Collagen; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Mice, Inbred BALB C; Molecular Targeted Therapy; Pyridones; Signal Transduction; Time Factors; Transforming Growth Factor beta; Triple Negative Breast Neoplasms; Tumor Burden; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays	2016
Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2017, Volume: 31, Issue:5 Topics: Adult; Aged; Cell Proliferation; Female; Fibroblasts; Hedgehog Proteins; Humans; Idiopathic Pulmonary Fibrosis; Kruppel-Like Transcription Factors; Male; Middle Aged; Nuclear Proteins; Pyridones; Signal Transduction; Transforming Growth Factor beta; Zinc Finger Protein Gli2	2017
Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro. PloS one, 2017, Volume: 12, Issue:2 Topics: Actins; Anti-Inflammatory Agents, Non-Steroidal; Cell Proliferation; Cells, Cultured; Extracellular Matrix; Fibroblasts; Fibronectins; Fibrosis; Gene Expression Regulation; Humans; Pyridones; Signal Transduction; Transforming Growth Factor beta	2017
Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production. Blood, 2017, 05-04, Volume: 129, Issue:18 Topics: Allografts; Animals; B-Lymphocytes; Bronchiolitis Obliterans; Chemokine CCL2; Disease Models, Animal; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Interleukin-17; Macrophages; Mice; Mice, Mutant Strains; Pulmonary Fibrosis; Pyridones; Skin Diseases; T-Lymphocytes, Helper-Inducer; Transforming Growth Factor beta	2017
Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium. BMC pulmonary medicine, 2017, 04-18, Volume: 17, Issue:1 Topics: Animals; Antioxidants; Basic-Leucine Zipper Transcription Factors; Bleomycin; Bronchoalveolar Lavage Fluid; Collagen Type I; Fibroblasts; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Heme Oxygenase-1; Interleukin-6; Lung; Male; Malondialdehyde; Membrane Proteins; Mice; Mice, Inbred C57BL; Myofibroblasts; NF-E2-Related Factor 2; Oxidative Stress; Pulmonary Fibrosis; Pyridones; RNA, Messenger; Transforming Growth Factor beta	2017
Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype. Respirology (Carlton, Vic.), 2018, Volume: 23, Issue:8 Topics: Actins; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cells, Cultured; Collagen; Culture Media, Conditioned; Drug Combinations; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Laminin; Phenotype; Phosphorylation; Primary Cell Culture; Proteoglycans; Pyridones; Signal Transduction; Smad3 Protein; STAT3 Transcription Factor; Transforming Growth Factor beta	2018
A Rnd3/p190RhoGAP pathway regulates RhoA activity in idiopathic pulmonary fibrosis fibroblasts. Molecular biology of the cell, 2018, 09-01, Volume: 29, Issue:18 Topics: Cell Line; Down-Regulation; Extracellular Matrix; Fibroblasts; Guanine Nucleotide Exchange Factors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Phenotype; Pyridones; Repressor Proteins; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Transforming Growth Factor beta; Up-Regulation	2018
Prevention of tracheal stenosis with pirfenidone after tracheotomy: An experimental study. The Laryngoscope, 2019, Volume: 129, Issue:5 Topics: Animals; Fibrosis; Immunohistochemistry; Inflammation; Interleukin-1beta; Pyridones; Rats; Rats, Sprague-Dawley; Tracheal Stenosis; Tracheotomy; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha	2019
Assessment of Topical Therapies for Improving the Optical Clarity Following Stromal Wounding in a Novel Ex Vivo Canine Cornea Model. Investigative ophthalmology & visual science, 2018, 11-01, Volume: 59, Issue:13 Topics: Actins; Administration, Ophthalmic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Connective Tissue Growth Factor; Cornea; Corneal Injuries; Corneal Opacity; Corneal Stroma; Dogs; Epithelium, Corneal; Histone Deacetylase Inhibitors; Immunohistochemistry; Lasers, Excimer; Models, Animal; Organ Culture Techniques; Pyridones; Re-Epithelialization; Real-Time Polymerase Chain Reaction; Transforming Growth Factor beta; Visual Acuity; Vorinostat; Wound Healing	2018
CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation. International journal of nanomedicine, 2019, Volume: 14 Topics: Animals; Apoptosis; Benzylamines; Cell Line; Cell Line, Tumor; Cell Survival; Cyclams; Drug Delivery Systems; Endocytosis; Hepatic Stellate Cells; Heterocyclic Compounds; Humans; Liposomes; Liver Cirrhosis; Mice; p38 Mitogen-Activated Protein Kinases; Pyridones; Rats; Receptors, CXCR4; Signal Transduction; Tissue Distribution; Transforming Growth Factor beta	2019
Pirfenidone alleviates concanavalin A-induced liver fibrosis in mice. Life sciences, 2019, Dec-15, Volume: 239 Topics: Animals; Collagen Type II; Collagen Type IV; Concanavalin A; Disease Models, Animal; Hepatic Stellate Cells; Liver; Liver Cirrhosis; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred BALB C; Pyridones; RNA, Messenger; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha	2019
Pirfenidone ameliorates the formation of choroidal neovascularization in mice. Molecular medicine reports, 2020, Volume: 21, Issue:5 Topics: Animals; Choroid; Choroidal Neovascularization; Disease Models, Animal; Fluorescein Angiography; Fluorescent Antibody Technique; Intravitreal Injections; Lasers; Male; Mice; Mice, Inbred C57BL; Pyridones; Retina; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A	2020
TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis. Annals of the rheumatic diseases, 2021, Volume: 80, Issue:12 Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Cell Differentiation; Collagen; Disease Models, Animal; Female; Fibroblasts; Fibrosis; Gene Expression Profiling; Humans; Interleukin-10; Lectins, C-Type; Lymphocytes; Male; Mice; Middle Aged; Myofibroblasts; Pyridones; Receptors, Immunologic; Scleroderma, Systemic; Skin; Transforming Growth Factor beta	2021
The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β. Cancer biology & therapy, 2022, 12-31, Volume: 23, Issue:1 Topics: Animals; Carcinoma, Renal Cell; Epithelial-Mesenchymal Transition; Female; Fibrosis; Humans; Kidney Neoplasms; Male; Mice; Pyridones; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Microenvironment	2022
Integrated bioinformatics analysis identifies established and novel TGFβ1-regulated genes modulated by anti-fibrotic drugs. Scientific reports, 2022, 02-23, Volume: 12, Issue:1 Topics: Adaptor Proteins, Vesicular Transport; Antifibrotic Agents; Cadherins; Cell Adhesion Molecule-1; Computational Biology; Extracellular Matrix Proteins; Female; Gene Expression Regulation; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Interleukins; Male; Membrane Proteins; Nerve Tissue Proteins; Pyridones; Racemases and Epimerases; Repressor Proteins; Tensins; Transforming Growth Factor beta	2022
Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis. Scientific reports, 2022, 11-30, Volume: 12, Issue:1 Topics: Animals; Disease Models, Animal; Esomeprazole; Idiopathic Pulmonary Fibrosis; Mice; Prospective Studies; Proton Pump Inhibitors; Retrospective Studies; Transforming Growth Factor beta	2022
Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF-β/SMAD pathway. Journal of cellular and molecular medicine, 2023, Volume: 27, Issue:3 Topics: Animals; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Humans; Mice; Signal Transduction; Smad Proteins; Transforming Growth Factor beta; Triple Negative Breast Neoplasms	2023